




The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharmacyclics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 156% points. The greatest weakness of Pharmacyclics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 358%, being 124% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	114,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,268
Liabilities, Non-Current	0
Other Assets	344
Other Compr. Net Income	-15
Other Expenses	0
Other Liabilities	410
Other Net Income	171
Other Revenues	8,233
Property and Equipment	1,312
Research and Development	34,482
Selling, General and Administrative Expense	9,125

Output Variable	Value in 1000 USD
Assets	116,352
Liabilities	14,678
Expenses	43,607
Revenues	8,233
Stockholders Equity	101,674
Net Income	-35,203
Comprehensive Net Income	-35,210
BaseVar	91,528
ECR before LimitedLiability	285%
Economic Capital Ratio	358%